ATE370960T1 - Verknüpfte peptid-nukleinsäuren - Google Patents

Verknüpfte peptid-nukleinsäuren

Info

Publication number
ATE370960T1
ATE370960T1 AT95928084T AT95928084T ATE370960T1 AT E370960 T1 ATE370960 T1 AT E370960T1 AT 95928084 T AT95928084 T AT 95928084T AT 95928084 T AT95928084 T AT 95928084T AT E370960 T1 ATE370960 T1 AT E370960T1
Authority
AT
Austria
Prior art keywords
peptide nucleic
nucleic acids
strands
peptide
pyrimidines
Prior art date
Application number
AT95928084T
Other languages
English (en)
Inventor
Michael Egholm
Peter Nielsen
Ole Buchardt
Kim Dueholm
Leif Christensen
James Coull
John Kiely
Michael Griffith
Original Assignee
Isis Pharmaceuticals Inc
Perseptive Biosystems Inc
Buchardt Dorte
Michael Egholm
Nielsen Peter Eigil
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc, Perseptive Biosystems Inc, Buchardt Dorte, Michael Egholm, Nielsen Peter Eigil filed Critical Isis Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE370960T1 publication Critical patent/ATE370960T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT95928084T 1994-07-15 1995-07-13 Verknüpfte peptid-nukleinsäuren ATE370960T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/275,951 US6451968B1 (en) 1991-05-24 1994-07-15 Peptide nucleic acids

Publications (1)

Publication Number Publication Date
ATE370960T1 true ATE370960T1 (de) 2007-09-15

Family

ID=23054499

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95928084T ATE370960T1 (de) 1994-07-15 1995-07-13 Verknüpfte peptid-nukleinsäuren

Country Status (7)

Country Link
US (1) US6451968B1 (de)
EP (1) EP0773950B1 (de)
JP (1) JP3326181B2 (de)
AT (1) ATE370960T1 (de)
AU (1) AU3196795A (de)
DE (1) DE69535575D1 (de)
WO (1) WO1996002558A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105286A1 (en) * 1991-05-24 2003-06-05 Michael Egholm Linked peptide nucleic acids
DK51092D0 (da) * 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US6350853B1 (en) 1993-04-26 2002-02-26 Peter E. Nielsen Conjugated peptide nucleic acids having enhanced cellular uptake
CA2255599C (en) 1996-04-25 2006-09-05 Bioarray Solutions, Llc Light-controlled electrokinetic assembly of particles near surfaces
US6617422B1 (en) 1997-05-23 2003-09-09 Peter Nielsen Peptide nucleic acid monomers and oligomers
US6300318B1 (en) * 1997-09-16 2001-10-09 Peter E. Nielsen Antibacterial and antibiotic methods using peptide nucleic acids and pharmaceutical compositions therefor
ATE478090T1 (de) 1997-10-27 2010-09-15 Boston Probes Inc SICH AUF ßPNA MOLECULAR BEACONSß BEZIEHENDE VERFAHREN, TESTSÄTZE UND ZUSAMMENSETZUNGEN
US20040063618A1 (en) * 2002-09-30 2004-04-01 Muthiah Manoharan Peptide nucleic acids having improved uptake and tissue distribution
US20040186071A1 (en) 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
AU3671099A (en) 1998-04-29 1999-11-16 Trustees Of Boston University Methods and compositions pertaining to pd-loops
GB9815933D0 (en) * 1998-07-23 1998-09-23 Secr Defence Detection method
CA2388991A1 (en) * 1998-11-11 2001-04-19 Peter E. Nielsen Conjugates between a peptides and a nucleic acid analog, such as a pna, lna or a morpholino
US6548651B1 (en) 1998-11-11 2003-04-15 Pantheco A/S Modified peptide nucleic acid (PNA) molecules
US9709559B2 (en) 2000-06-21 2017-07-18 Bioarray Solutions, Ltd. Multianalyte molecular analysis using application-specific random particle arrays
AU784561B2 (en) * 2000-06-23 2006-05-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Positively-charged peptide nucleic acid analogs with improved properties
US7256275B2 (en) 2001-03-09 2007-08-14 Boston Probes, Inc. Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation
US7262063B2 (en) 2001-06-21 2007-08-28 Bio Array Solutions, Ltd. Directed assembly of functional heterostructures
CA2497740C (en) 2001-10-15 2011-06-21 Bioarray Solutions, Ltd. Multiplexed analysis of polymorphic loci by probe elongation-mediated detection
US7041453B2 (en) 2002-08-22 2006-05-09 Bioarray Solutions Ltd. Molecular constructs and methods of use for detection of biochemical reactions
AU2003298655A1 (en) 2002-11-15 2004-06-15 Bioarray Solutions, Ltd. Analysis, secure access to, and transmission of array images
ATE488604T1 (de) * 2003-05-20 2010-12-15 Investigen Inc System zum nachweis von polynukleotiden
CA2539824C (en) 2003-09-22 2015-02-03 Xinwen Wang Surface immobilized polyelectrolyte with multiple functional groups capable of covalently bonding to biomolecules
DE10346721A1 (de) * 2003-10-08 2005-05-04 Holger Kalthoff Oligonukleotide, diese enthaltende Mittel und deren Verwendung
CA2544041C (en) 2003-10-28 2015-12-08 Bioarray Solutions Ltd. Optimization of gene expression analysis using immobilized capture probes
US20050260131A1 (en) * 2004-05-20 2005-11-24 General Electric Company Pharmaceuticals for enhanced delivery to disease targets
US7543412B2 (en) * 2004-06-14 2009-06-09 Haworth, Ltd. Wall panel edge rail connector arrangement
US7848889B2 (en) 2004-08-02 2010-12-07 Bioarray Solutions, Ltd. Automated analysis of multiplexed probe-target interaction patterns: pattern matching and allele identification
US7306785B2 (en) * 2004-09-23 2007-12-11 General Electric Company Multifunctional cross-bridged tetraaza macrocyclic compounds and methods of making and using
CN101495647B (zh) 2005-06-02 2014-12-17 阿德万德克斯公司 用于微生物分析的肽核酸探针
WO2006137786A1 (en) 2005-06-20 2006-12-28 Avaris Ab Hybridization-stabilizing construct
US8658608B2 (en) * 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
US8021839B2 (en) * 2006-02-24 2011-09-20 Investigen, Inc. Methods and compositions for detecting polynucleotides
AU2007281535A1 (en) 2006-08-01 2008-02-07 Applied Biosystems, Llc. Detection of analytes and nucleic acids
US20080096193A1 (en) * 2006-10-24 2008-04-24 Charles Robert Bupp Methods and compositions for detecting polynucleotides
WO2008072933A1 (en) * 2006-12-15 2008-06-19 Panagene Inc. Peptide nucleic acids conjugated with multi -amine linkers and nucleic acid detecting device using the same
US7771947B2 (en) 2007-02-23 2010-08-10 Investigen, Inc. Methods and compositions for rapid light-activated isolation and detection of analytes
US8916531B2 (en) 2007-11-20 2014-12-23 Isis Pharmaceuticals, Inc. Modulation of CD40 expression
US7964355B2 (en) * 2009-02-17 2011-06-21 Investigen, Inc. Assays based on detection of photobleaching reaction products from dye catalytic complex
WO2011017315A2 (en) * 2009-08-03 2011-02-10 Recombinetics, Inc. Methods and compositions for targeted gene modification
TW201726630A (zh) * 2009-10-16 2017-08-01 梅林塔療法公司 抗微生物性化合物及其製造與使用方法
US9216979B2 (en) 2009-10-16 2015-12-22 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
WO2011047320A2 (en) 2009-10-16 2011-04-21 Rib-X Pharmaceuticals, Inc. Antimicrobial compounds and methods of making and using the same
US20140170653A1 (en) 2011-04-15 2014-06-19 Life Technologies Corporation Chemical ligation
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
KR20160070066A (ko) 2013-09-09 2016-06-17 멜린타 테라퓨틱스, 인크. 항균 화합물, 및 이의 제조 방법 및 이용 방법
EP3038623A4 (de) 2013-09-09 2017-04-19 Melinta Therapeutics, Inc. Antimikrobielle verbindungen und verfahren zur herstellung und verwendung davon
BR112016016130A2 (pt) 2014-01-10 2017-08-08 Glaxosmithkline Ip No 2 Ltd Compostos e métodos
ES2966886T3 (es) 2014-05-09 2024-04-24 Univ Yale Partículas recubiertas con poliglicerol hiperramificado y métodos de elaboración y uso de las mismas
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
EP3633047B1 (de) 2014-08-19 2022-12-28 Pacific Biosciences of California, Inc. Verfahren zur sequenzierung von nukleinsäuren basierend auf einer anreicherung von nukleinsäuren
CA2979342A1 (en) 2015-03-11 2016-09-15 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
CA3001065A1 (en) 2015-10-14 2017-04-20 Xiaoxi WEI Compositions and methods for reducing ice crystal formation
JP2019508037A (ja) 2016-02-16 2019-03-28 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔ 標的化遺伝子編集を増強するための組成物およびその使用方法
WO2017193016A1 (en) 2016-05-06 2017-11-09 Melinta Therapeutics, Inc. Antimicrobials and methods of making and using same
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986005519A1 (en) 1985-03-15 1986-09-25 James Summerton Polynucleotide assay reagent and method
US5235033A (en) * 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) * 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
WO1990002749A1 (en) 1988-09-01 1990-03-22 Forskningscenter Risø Peptide synthesis method and solid support for use in the method
DE3924705A1 (de) 1989-07-26 1991-01-31 Boehringer Mannheim Gmbh Heterobifunktionelle verbindungen
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
DK51092D0 (da) 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US5539082A (en) * 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
JPH06510203A (ja) 1991-08-30 1994-11-17 ザ・ジョーンズ・ホプキンス・ユニバーシティ プリン塩基類似体を含むヌクレオシドオリゴマーを用いる二重鎖ｄｎａの三重らせん複合体の形成
MX9207334A (es) 1991-12-18 1993-08-01 Glaxo Inc Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene
WO1993018187A1 (en) 1992-03-13 1993-09-16 California Institute Of Technology Triple helix recognition of dna
WO1994005268A1 (en) 1992-09-04 1994-03-17 Baylor College Of Medicine Novel triplex forming oligonucleotides and methods for their use
US5324483B1 (en) 1992-10-08 1996-09-24 Warner Lambert Co Apparatus for multiple simultaneous synthesis
AU684774B2 (en) 1992-12-08 1998-01-08 Genta Incorporated Formation of triple helix complexes using a novel motif

Also Published As

Publication number Publication date
EP0773950A4 (de) 2000-05-17
WO1996002558A1 (en) 1996-02-01
JP3326181B2 (ja) 2002-09-17
US6451968B1 (en) 2002-09-17
JPH10503759A (ja) 1998-04-07
EP0773950B1 (de) 2007-08-22
EP0773950A1 (de) 1997-05-21
DE69535575D1 (de) 2007-10-04
AU3196795A (en) 1996-02-16

Similar Documents

Publication Publication Date Title
ATE370960T1 (de) Verknüpfte peptid-nukleinsäuren
FI953743A0 (fi) Keratolyyttistä ja/tai finnitaudinvastaista aktiivisuutta omaavia kosmeettisia koostumuksia, niiden valmistus ja käyttö
FI956019A7 (fi) Eristettyjä peptidejä, jotka muodostavat komplekseja MHC-molekyyli HLA -C-klooni-10:n kanssa, ja niiden käyttö
EP0986372A4 (de) Vesikuläre komplexe und verfahren zu deren herstellung und verwendung
ATE544776T1 (de) Chimäre dna-bindeproteine
DK1029870T3 (da) Hybride immunglobuliner til anvendelse i terapeutiske fremgangsmåder
ATE225369T1 (de) Doppelsträngige peptidenukleinsäuren
DK0586474T3 (da) Peptionukleinsyrer
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
ATE391789T1 (de) Verwendung einer vielzahl von rekombinationsstellen mit einzigartiger spezifität beim rekombinatorischen klonen
FI965201L (fi) Puhdistetut Polyporus-lakkaasit ja niitä koodaavat nukleiinihapot
DE69505804D1 (de) Afamin: ein menschliches serum albumin ähnliches protein
EP0585257A4 (de) Für natürliche killerzellen spezifische dna- und aminosäuresequenz.
DK0705846T3 (da) Höjmolekylære og lavmolekylære fraktioner af von Willebrand-faktor
CA2278028A1 (en) Methods for improving transformation efficiency
ATE387458T1 (de) Fas-antigenbindender ligand
DK54184D0 (da) Dna-sekvenser,rekombinations-dna-molekyler samt fremgangsmaader til fremstilling af human(interleukin)to-lignende polipeptider
DE69434384D1 (de) Metalkomplexbildner
FI972703L (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
DE69332203D1 (de) Multimerische mehrzweckwirkstoffe gegen thrombose
FI952738L (fi) Stabiiliproteiini, fosfolipidikoostumuksia ja menetelmiä
SE9602822D0 (sv) New receptor
EA200000567A1 (ru) Бактериальные плазмиды
FR2692903B1 (fr) Nouveaux complexes metalliferes 1:2 asymetriques, leur preparation et leur utilisation comme colorants anioniques.
UA42797C2 (uk) Похідні хінолон- і нафтиридонкарбонової кислоти та похідні ізоіндолу для їх одержання

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties